RT Journal Article T1 Splenic irradiation before hematopoietic stem cell transplantation for chronic myeloid leukemia: long-term follow-up of a prospective randomized study. A1 Gratwohl, Alois A1 Iacobelli, Simona A1 Bootsman, Natalia A1 van Biezen, Anja A1 Baldomero, Helen A1 Arcese, William A1 Arnold, Renate A1 Bron, Dominique A1 Cordonnier, Catherine A1 Ernst, Peter A1 Ferrant, Augustin A1 Frassoni, Francesco A1 Gahrton, Gösta A1 Richard, Carlos A1 Kolb, Hans Jochem A1 Link, Hartmut A1 Niederwieser, Dietger A1 Ruutu, Tapani A1 Schattenberg, Anton A1 Schmitz, Norbert A1 Torres-Gomez, Antonio A1 Zwaan, Ferry A1 Apperley, Jane A1 Olavarria, Eduardo A1 Kröger, Nicolaus A1 Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation EBMT, K1 CML K1 HSCT K1 Long-term follow-up K1 Randomized trial K1 Splenic irradiation AB In the context of discussions on the reproducibility of clinical studies, we reanalyzed a prospective randomized study on the role of splenic irradiation as adjunct to the conditioning for hematopoietic stem cell transplantation (HSCT) for chronic myeloid leukemia (CML). Between 1986 and 1989, a total of 229 patients with CML were randomized; of these, 225 (98 %; 112 with, 113 without splenic irradiation) could be identified in the database and their survival updated. Results confirmed the early findings with no significant differences in all measured endpoints (overall survival at 25 years: 42.7 %, 32.0-52.4 % vs 52.9 %, 43.2-62.6 %; p = 0.355, log rank test). Additional splenic irradiation failed to reduce relapse incidence. It did not increase non-relapse mortality nor the risk of late secondary malignancies. Comforting are the long-term results from this predefined consecutive cohort of patients: more than 60 % were alive at plus 25 years when they were transplanted with a low European Society for Blood and Marrow Transplantation (EBMT) risk sore. This needs to be considered today when treatment options are discussed for patients who failed initial tyrosine kinase inhibitor therapy and have an available low risk HLA-identical donor. YR 2016 FD 2016-03-19 LK http://hdl.handle.net/10668/9932 UL http://hdl.handle.net/10668/9932 LA en DS RISalud RD Apr 7, 2025